tks for your math. See, this is a long term story. If you believe they can materialize the huge potential in the target market to include sepsis etc., the stock is not expensive, all opposite. We notice in Europe, namely in Germany, Austria and Switzerland, not to mention the coverage of the countries by Fresenius Medical, a steadily growing acceptance of the filter. One of the main revenue trigger ahead will be the approval by the US authority, which I believe is not so far away, must be in June/July.